Seven Fleet Capital Management LP Sells 16,086 Shares of Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP decreased its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 19.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,723 shares of the company’s stock after selling 16,086 shares during the quarter. Dianthus Therapeutics comprises about 1.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 21st biggest holding. Seven Fleet Capital Management LP owned about 0.12% of Dianthus Therapeutics worth $6,309,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Dianthus Therapeutics during the second quarter valued at $401,990,000. Wellington Management Group LLP boosted its stake in Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after purchasing an additional 634,099 shares in the last quarter. Vestal Point Capital LP grew its position in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the last quarter. Finally, TCG Crossover Management LLC increased its stake in Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $108.10 on Friday. The stock has a market capitalization of $5.91 billion, a price-to-earnings ratio of -26.05 and a beta of 1.24. Dianthus Therapeutics, Inc. has a 1-year low of $24.49 and a 1-year high of $117.88. The business’s fifty day moving average price is $105.23 and its 200-day moving average price is $89.08.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Insiders Place Their Bets

In related news, Director Anne McGeorge sold 7,750 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 283,678 shares of company stock valued at $29,672,400. 3.02% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Raymond James Financial restated a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Truist Financial upped their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $126.92.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.